[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502003":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":59,"collaborators":61,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":26,"eligibilityCriteria":70,"healthyVolunteers":66,"sex":71,"minAge":72,"maxAge":26,"enrollmentInfo":73,"targetDuration":26,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":26,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Weill Medical College of Cornell University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Real tDCS stimulation","EXPERIMENTAL","Subjects randomized to receive real\u002Factive electrical stimulation.",[13],"Device: Real Soterix Mini-CT tDCS stimulator",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham tDCS stimulation","SHAM_COMPARATOR","Subjects randomized to receive sham\u002Fnon-activating electrical stimulation.",[19],"Device: Sham Soterix Mini-CT tDCS stimulator",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Real Soterix Mini-CT tDCS stimulator","Real transcranial electrical stimulation at 2mA intensity will be delivered to the left dorsolateral prefrontal cortex, 20 minutes\u002Fday, 14-day duration.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Sham Soterix Mini-CT tDCS stimulator","Sham stimulation to the left dorsolateral prefrontal cortex, 20 minutes\u002Fday, 14-day duration. The device will ramp up and ramp down current delivery from 0 mA -2 mA - 0 mA over 30 seconds at the start of the 20-minute protocol with no active stimulation until the end of the 20 minutes, at which time the 30-second ramp up\u002Framp down will be repeated.",[15],[32],{"name":33,"affiliation":5,"role":34},"Joan M Stilling, MD, MS","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},"Zhiyan Yang, M.A.","CONTACT","(212) 746-1509","rehabresearch@med.cornell.edu",[42],{"facility":43,"status":44,"city":45,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Weill Cornell Medicine, 525 E. 68th St, Baker Pavilion, F-2106","RECRUITING","New York","10065","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-74.00597,40.71427,{"lat":53,"lon":52},[56,57],{"name":37,"role":38,"phone":39,"phoneExt":26,"email":40},{"name":58,"role":34,"phone":26,"phoneExt":26,"email":26},"Joan Stilling, MD, MS",{"type":60,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[62],{"name":63,"class":6},"American Heart Association","100502003","phase-2-transcranial-direct-current-stimulation-for-post-stroke-fatigue-100502003",false,"NCT05816603","Transcranial Direct Current Stimulation for Post-stroke Fatigue","Home-based Post-stroke Fatigue Treatment Using Transcranial Direct Current Stimulation (tDCS)","Inclusion Criteria:\n\n* Male or female patients aged \\>18 years\n* Greater than 3 months from first hemorrhagic or ischemic stroke (subacute to chronic), confirmed through neuroimaging (CT or MRI).\n* Fatigue severity score average \\>4 (severe fatigue)\n* Willingness to remain stable on pharmacologic therapy through the duration of the study.\n* Availability of a caregiver, family member, or friend to be present during the administration of the tDCS intervention.\n\nExclusion Criteria:\n\n* Metal in the head (except mouth) or implanted cranial or thoracic devices (i.e. pacemaker, DBS stimulator)\n* History of seizure\n* History of moderate to severe traumatic brain injury\n* A score of 10 or more on the PHQ-9 or GAD-7 scale, suggestive of moderate to severe depression\u002Fanxiety.\n* A score of less than 21 on the MoCA suggesting major neurocognitive disorder.\n* Signs of skin rash, infection, or laceration in the supraorbital region where the tDCS will be applied.\n* Inability to provide informed consent\n* Other major neurological, medical, or psychiatric illnesses that could confound results in the opinion of the site investigator.","ALL","18 Years",{"count":74,"type":75},24,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The investigators hypothesize that delivery of anodal tDCS to the left frontal head region will reduce fatigue severity following stroke.",[81,82],"Fatigue","Stroke Rehabilitaion","2026-02-24",{"date":85,"type":86},"2026-02-27","ACTUAL",{"date":88,"type":86},"2023-05-23",{"date":90,"type":75},"2027-12",{"name":5,"class":6},1]